Novartis International AG is a multinational pharmaceutical company based in Basel, Switzerland, ranking number three in sales among the world-wide industry.[when?] Company sales totalled 36.173 billon US$ in 2008. Currently,[when?] Novartis is the sixth largest pharmaceutical company in terms of revenue ($41.5 billion in 2009) with a profit margin of about 20%, which is the same as its industry competitors. Novartis profits were down by 31% from 2007 levels. Novartis manufactures such drugs as clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate and (Gleevec / Glivec). Additional agents include ciclosporin (Neoral / Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), and others. Renamed to Novartis following an acquisition by Ciba-Geigy, it owns Sandoz, a large manufacturer of generic drugs. The company formerly owned the Gerber Products Company, a major infant and baby products producer, but sold it to Nestlé on 1 September 2007.
Campaign Finance$5,191,178 Given
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
state-level data is not available in bulk for 2014. for current state data, browse http://followthemoney.org/
- PAC Color Block
- Organization's PAC(s)
- Employee Color Block
- Associated Individuals
Republicans vs. Democratsin dollars. "Other" includes 3rd parties and organizations without official party affiliation.
State vs. Federalin dollars
Top PAC Recipients
- PAC Color Block
- Organization's PAC(s)
- Employee Color Block
- Associated Individuals
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of Novartis Corp
Names of Lobbyists
Firm Hired Amount Novartis Corp $75,854,515 Novartis Vaccines & Diagnostics $2,031,000 Fleishman-Hillard Inc $225,000 Keaney Consulting $120,000 Ruder Finn Inc $20,000
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Medicare & Medicaid,
- Fed Budget & Appropriations,
- Copyright, Patent & Trademark,
- Medical Research & Clin Labs,
- Government Issues,
Most Frequently Disclosed Bills
Bill No. Title H.R.3590 Service Members Home Ownership Tax Act of 2009 H.R.1908 Patent Reform Act of 2007 H.R.3200 America's Affordable Health Choices Act of 2009 H.R.1548 Pathway for Biosimilars Act H.R.1 American Recovery and Reinvestment Act of 2009 H.R.1427 Promoting Innovation and Access to Life-Saving Medicine Act S.301 Physician Payments Sunshine Act of 2009 S.1145 Patent Reform Act of 2007 S.1695 Biologics Price Competition and Innovation Act of 2007 H.R.1956 Patient Protection and Innovative Biologic Medicines Act of 2007
Recent Lobbying Contracts
Date Registrant Summary March 12, 2015 Monument Policy Group Trade: Issues related to Trade Promotion Authority; Trans-Pacific Partnership; general market access issues, intellectual property, and substandard drugs. Health: Issues related to domestic healthcare including, Medicare Sustainable Growth Rate; biosimilars; Part D; orphan drugs; medical devices. Tax: Issues related to corporate tax reform; tax extenders; orphan drugs View registration
RegulationsMentioned in 62 dockets; Submitted to 6 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Novartis Corp" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for Novartis Corp
- Toggle 1 USTR Request for Comments on Proposed Trans-Pacific Partnership Trade Agreement 2009
- Toggle 1 IRS Branded Prescription Drug Fee 2011
- Toggle 1 OSHA ERGONOMICS PROGRAM 2006
- Toggle 1 USTR TPP 2009
- Toggle 1 USTR Request for Comments on Negotiating Objectives With Respect to Mexico’s Participation in the Proposed Trans-Pacific Partnership Trade Agreement 2012
- Toggle 1 USTR Request for Comments on Negotiating Objectives With Respect to Canada’s Participation in the Proposed Trans-Pacific Partnership Trade Agreement 2012
Mentions in Document Text
View all mentions data for Novartis Corp
- Toggle 5 FDA Patent Extension Application for TEKTURNA (Aliskiren hemifumarate), U.S. Patent No. 5,559,111 2007
- Toggle 4 FDA Patent Extension for Inspra (eplerenone), 4,559,332 2003
- Toggle 4 FDA Patent Term Application for Zometa No. 4,939,130 2002
- Toggle 3 FDA Patent Term Extension Application for EXELON PATCH (rivastigmine), U.S. Patent No. 5,602,176 2008
- Toggle 3 FDA Patent extension application 5,849,911 for Reyataz ( atazanavir sulfate ) 2004
- Toggle 3 EPA Standards Applicable to Generators of Hazardous Waste; Subpart K- Standards Applicable to Academic Laboratories 2003
- Toggle 2 USTR Request for Comments Concerning Free Trade Agreement With the Republic of Korea 2009
- Toggle 2 USTR Request for Comments on Mexico’s Expression of Interest in the Proposed Trans-Pacific Partnership Trade Agreement 2011
- Toggle 2 EPA National Pollutant Discharge Elimination System (NPDES) General Permit for Discharges from the Application of Pesticides 2010
- Toggle 2 FDA Agency Information Collection Activities; Proposed Collection; Comment Request; Experimental Study: Examination of Corrective DTC Television Advertising 2012
EPA Violations6 Enforcement Actions
Figures are based on data from the Environmental Protection Agency’s ECHO website. The ECHO database contains federal and state environmental enforcement actions. Data displayed here includes only those actions that began after 2000 and resulted in fines of over $1 million.
Actions where the company was the sole defendant are listed first. Actions where the company is one of multiple defendants are listed subsequently.
For more information see our EPA methodology page.
|Ciba Specialty Chemicals Corp., Et Al||Novartis Corp (+1 others)||2002||Toms River, Nj||$92,250,000|
|Agere Systems, Et Al||Novartis Corporation (+138 others)||2007||Elkton, Md||$11,300,000|
|Advanced Environmental Technology Corp.||Novartis Pharmaceuticals Corp. (+13 others)||2007||Sayreville Boro, Nj; ...||$9,863,579|
|Old Southington Landfill||Ciba Corporation & Novartis Corporation (+85 others)||2009||Southington, Ct||$4,248,450|
|Abb, Inc. Et Al (Spectron Deminimis Settlement)||Novartis Corporation (+547 others)||2003||Elkton, Md||$2,803,841|
|Chevron Environmental Management Company For Itself And On Behalf Of Kewannee Industries, Inc. Et Al||Novartis Pharmaceuticals Corp succ to Ciba-Giegy (+2 others)||2005||Chatham Twp, Nj||$2,000,000|
Advisory Committees1 person on 1 committee
Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.
The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.
Table shows employees of "Novartis Corp" that sat on federal advisory committees.
- Toggle National Science Foundation 1 person on 1 committee